NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVBXXXX and the CUSIP is 63937X103. A total of 55 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $41,000 | +105.0% | 299,000 | +54.1% | 0.00% | +33.3% |
| Q4 2018 | $20,000 | -55.6% | 194,000 | 0.0% | 0.00% | -40.0% |
| Q3 2018 | $45,000 | +2.3% | 194,000 | 0.0% | 0.01% | 0.0% |
| Q2 2018 | $44,000 | -37.1% | 194,000 | 0.0% | 0.01% | -44.4% |
| Q1 2018 | $70,000 | +14.8% | 194,000 | +14.8% | 0.01% | +28.6% |
| Q4 2017 | $61,000 | +771.4% | 169,000 | +956.2% | 0.01% | +600.0% |
| Q3 2017 | $7,000 | – | 16,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Platinum Management (NY) LLC | 15,575,946 | $14,711,000 | 89.51% |
| Financial Advisory Group | 10,000 | $356,000 | 0.17% |
| COMMERZBANK AKTIENGESELLSCHAFT /FI | 6,704,067 | $6,332,000 | 0.05% |
| LifePlan Financial Group, Inc | 28,810 | $27,000 | 0.02% |
| Greenwich Wealth Management LLC | 65,066 | $61,000 | 0.02% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 649,880 | $614,000 | 0.01% |
| LYNCH & ASSOCIATES/IN | 18,000 | $17,000 | 0.01% |
| SII INVESTMENTS INC/WI | 90,315 | $86,000 | 0.01% |
| Stratos Wealth Partners, LTD. | 42,535 | $40,000 | 0.00% |
| SVB WEALTH LLC | 46,262 | $44,000 | 0.00% |